Xofigo® - radium Ra 223 dichloride injection

Important Safety Information

  • Contraindications: Xofigo is contraindicated in women who are or may become pregnant. Xofigo can cause fetal harm when
    administered to a pregnant woman
  • Bone Marrow Suppression: In the randomized trial, 2% of patients in the Xofigo arm experienced bone marrow failure or ongoing
    pancytopenia, compared to no patients treated with placebo. Continue reading below
PATIENTS Learn more about
your treatment with Xofigo >
Find an Administering Facility Near You

Indication

Xofigo® (radium Ra 223 dichloride) injection is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.

Important Safety Information

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call
1-800-FDA-1088. For important risk and use information about Xofigo, please see the Full Prescribing Information.